# OnCo record romidepsin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/romidepsin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "romidepsin" ;
  schema:name "Romidepsin"@en ;
  schema:description "Romidepsin is an epigenetic drug for T-cell lymphomas of the skin and lymph nodes; its US lymph-node indication was withdrawn when a confirmatory trial failed."@en ;
  schema:url <https://onco.cc/drugs/romidepsin/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Romidepsin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7363205> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=romidepsin> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Class I HDAC inhibitor (cyclic peptide)" ;
  schema:alternateName "Istodax" ;
  onco:approval "US 2009: Cutaneous T-cell lymphoma after ≥1 systemic therapy", "US 2011: Peripheral T-cell lymphoma after ≥1 therapy" ;
  onco:acceleratedApproval "US 2011-06-16: Peripheral T-cell lymphoma in patients who have received at least one prior therapy", "US 2020-03-13: Formulation: Treatment of peripheral T-cell lymphoma in adults who have received at least one prior therapy" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct04747236/>, <https://onco.cc/trials/nct00106431/>, <https://onco.cc/trials/nct00112463/> .